与抗节律药物相关的前节律失常:FDA不良事件报告系统的全面不成比例分析
Feifei Wang1, Bingfeng Zhou2, Hongwei Sun2
1Department of Pharmacy, Hefei BOE Hospital, Hefei, China.
Frontiers in pharmacology
|May 30, 2023
概括
这项研究发现,抗心律失常药物 (AAD) 与心律失常有关,风险因药物和相互作用而异. 早期识别和管理这些AAD相关的心律失常对于患者的安全至关重要.
科学领域:
- 药监和药物安全 药监和药物安全
- 心脏病学和电生理学.
- 临床药理学 临床药理学
背景情况:
- 抗心律失常药物 (AADs) 对于控制心律失常是必不可少的,但也可以诱导心律失常.
- 了解与不同AAD及其相互作用相关的特定风险对于安全的临床实践至关重要.
- 涉及ADS的药理学药物相互作用可能会改变它们的安全性,增加心律失常风险.
研究的目的:
- 为了确定各种抗心律失常药物 (AADs) 和心律失常之间的关联.
- 为了确定与单一治疗相比,与ADS的药理学药物相互作用是否会增加与ADS相关的心律失常的风险.
- 分析AAD相关心律失常的临床特征和发病时间.
主要方法:
- 在FAERS数据 (2016年1月至2022年6月) 上使用报告几率比率 (ROR) 和信息组件 (IC) 的不成比例分析.
- 包括AD单一疗法和同时使用药理动力学相互作用剂.
- 致命和非致命性心律失常病例之间的临床特征的比较和病发时间的分析.
主要成果:
- 确定了11,754起与ADD相关的心律失常报告,主要在老年人中.
- 在所有AAD单一治疗中发现了心律失常的显著安全信号 (ROR从4.86到11.07).
- 特定的AAD显示了特定类型的心律失常的高ROR,并且相对于单独的amiodarone,sofosbuvir加上amiodarone显著增加了心律失常风险.
结论:
- 与ADD相关的心律失常的风险和频谱在各种ADD及其组合中不同.
- 药物动力学相互作用,如索福斯布维尔和阿米奥达龙,可以显著增加心律失常的风险.
- 在临床环境中,迅速识别和管理AAD相关的心律失常至关重要.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
784
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
784
Disturbances in Heart Rhythm
1.0K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.0K
Pharmacovigilance
916
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
916
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Dysrhythmias VI: Management of Dysrhythmias
19
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
19
Mechanism of Cardiac Arrhythmias
972
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
972


